View More Recent Stories
-
Synta Pharma's (SNTA) Sees Encouraging Physician Feedback On Ganetespib - Jefferies
-
Rigel Pharma (RIGL) Plans to Shift Fostamatinib Focus From RA to ITP an 'Incremental Positive' - Jefferies
-
Jefferies Starts Stemline Therapeutics (STML) at Buy, Sees 77% Upside
-
CaPre to Have Minimal Impact on Amarin (AMRN) Vascepa Sales - Jefferies

